Search

Displaying results 2301 - 2310 of 10000 in total
  1. Drug

    Crotamiton

    go.drugbank.com/drugs/DB00265
    Approved

    Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … discovered that M1 and M4 muscarinic acetylcholine receptors are highly expressed in brain regions that are implicated in cognition.

  3. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.

  4. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

  5. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs

  6. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.

  7. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.

  8. Drug

    Nisoldipine

    go.drugbank.com/drugs/DB00401
    Approved

    Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. … It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

    International brands: Ji Ni Le Er
  9. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
  10. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with